医学
干细胞
间充质干细胞
胚胎干细胞
干细胞疗法
祖细胞
诱导多能干细胞
旁分泌信号
心肌梗塞
再生医学
间充质干细胞的临床应用
再生(生物学)
干细胞移植修复关节软骨
细胞疗法
成体干细胞
病理
生物信息学
心脏病学
内科学
细胞生物学
生物
生物化学
受体
基因
作者
Theodora M. Stougiannou,Konstantinos Christodoulou,Ioannis Dimarakis,Dimitrios Mikroulis,Dimos Karangelis
摘要
Despite improvements in contemporary medical and surgical therapies, cardiovascular disease (CVD) remains a significant cause of worldwide morbidity and mortality; more specifically, ischemic heart disease (IHD) may affect individuals as young as 20 years old. Typically managed with guideline-directed medical therapy, interventional or surgical methods, the incurred cardiomyocyte loss is not always completely reversible; however, recent research into various stem cell (SC) populations has highlighted their potential for the treatment and perhaps regeneration of injured cardiac tissue, either directly through cellular replacement or indirectly through local paracrine effects. Different stem cell (SC) types have been employed in studies of infarcted myocardium, both in animal models of myocardial infarction (MI) as well as in clinical studies of MI patients, including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), Muse cells, multipotent stem cells such as bone marrow-derived cells, mesenchymal stem cells (MSCs) and cardiac stem and progenitor cells (CSC/CPCs). These have been delivered as is, in the form of cell therapies, or have been used to generate tissue-engineered (TE) constructs with variable results. In this text, we sought to perform a narrative review of experimental and clinical studies employing various stem cells (SC) for the treatment of infarcted myocardium within the last two decades, with an emphasis on therapies administered through thoracic incision or through percutaneous coronary interventions (PCI), to elucidate possible mechanisms of action and therapeutic effects of such cell therapies when employed in a surgical or interventional manner.
科研通智能强力驱动
Strongly Powered by AbleSci AI